News | May 12, 2026
CORONA Remedies FY26 revenue rises 17.3% to Rs. 1,403 crore
The company’s PAT rose 43.7% year-on-year to Rs. 45.3 crore in Q4FY26 from Rs. 31.5 crore
The company’s PAT rose 43.7% year-on-year to Rs. 45.3 crore in Q4FY26 from Rs. 31.5 crore
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Subscribe To Our Newsletter & Stay Updated
